Robert T Winn

US Patent:

8304389, Nov 6, 2012

Filed:

May 13, 2011

Appl. No.:

13/107866

Inventors:

John M. Harlan - Seattle WA, US
Robert K. Winn - Bainbridge Island WA, US
Akiko Iwata - Seattle WA, US
Joan Tupper - Seattle WA, US
John Li - San Francisco CA, US

Assignee:

University of Washington through its Center for Commercialization, a Public Institution of Higher Education - Seattle WA

International Classification:

A61K 38/16

US Classification:

514 187, 514 11, 514 212, 514 213

Abstract:

In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal.

US Patent:

20010006656, Jul 5, 2001

Filed:

Feb 17, 1999

Appl. No.:

09/251707

Inventors:

JOHN M. HARLAN - SEATTLE WA, US
ROBERT K. WINN - BAINBRIDGE ISLAND WA, US
LI LIU - REDMOND WA, US

Assignee:

UNIVERSITY OF WASHINGTON

International Classification:

A61K009/00

US Classification:

424/400000

Abstract:

The present invention provides an aerosol formulation of a 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor. The HMG-CoA reductase inhibitor can be, for example, a statin such as lovastatin, pravastatin, simvastatin, cerivastatin, fluvastatin, atorvastatin or mevastatin. The invention also provides a method of treating a pulmonary disease with an aerosol formulation of a HMG-CoA reductase inhibitor.

US Patent:

20100297094, Nov 25, 2010

Filed:

Feb 1, 2010

Appl. No.:

12/697982

Inventors:

John M. Harlan - Seattle WA, US
Robert K. Winn - Bainbridge Island WA, US

International Classification:

A61K 35/26
A61K 35/12
A61P 9/10
A61P 3/10
A61P 37/06
A61P 35/00
A61P 29/00
A61P 11/00

US Classification:

424 9371, 424 931, 424 937

Abstract:

Methods and compositions for the treatment or prevention of diseases or disorders including media conditioned by mesenchymal stem cells and BCL2A1 are provided. Methods for the production of therapeutic or preventative compositions contacted with BCL2A1 are also provided.

US Patent:

20110021433, Jan 27, 2011

Filed:

Feb 1, 2010

Appl. No.:

12/697978

Inventors:

John M. Harlan - Seattle WA, US
Robert K. Winn - Seattle WA, US
Akiko Iwata - Seattle WA, US

International Classification:

A61K 38/16
A61K 38/10
A61P 9/00

US Classification:

514 164

Abstract:

The invention provides methods for inhibiting cell death or inflammation in a mammal brought about by diseases or conditions such as heart failure, wherein the method comprises administering to a mammal in need thereof a Bcl protein in an amount sufficient to inhibit cell death and inflammation in the mammal.

US Patent:

20110082072, Apr 7, 2011

Filed:

Oct 4, 2005

Appl. No.:

11/576591

Inventors:

John M. Harlan - Seattle WA, US
Robert K. Winn - Bainbridge Island WA, US
Akiko Iwata - Seattle WA, US
Joan Tupper - Seattle WA, US
John Li - Santa Monica CA, US

Assignee:

University of Washington - Seattle WA

International Classification:

A61K 38/17
C40B 30/06
A61P 43/00

US Classification:

514 14, 506 10, 514 206

Abstract:

In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal.

US Patent:

20110263510, Oct 27, 2011

Filed:

Nov 8, 2007

Appl. No.:

12/514436

Inventors:

John M. Harlan - Seattle WA, US
Robert K. Winn - Bainbridge Island WA, US

International Classification:

A61K 38/17
A61P 43/00
A61K 38/10

US Classification:

514 189

Abstract:

Methods are provided for inhibiting cell death or inflammation in a mammal concurrent with or after the onset of a condition expected to lead to cell death or inflammation. The methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. Methods are also provided for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal concurrent with or after the onset of a condition expected to lead to cell death or inflammation.

US Patent:

20130053329, Feb 28, 2013

Filed:

Oct 26, 2012

Appl. No.:

13/661411

Inventors:

University of Washington - Seattle WA, US
Robert K. Winn - Bainbridge Island WA, US
Akiko Iwata - Seattle WA, US
Joan Tupper - Seattle WA, US
John Li - San Francisco CA, US

Assignee:

UNIVERSITY OF WASHINGTON - Seattle WA

International Classification:

A61K 38/17
A61P 29/00
A61P 43/00

US Classification:

514 189, 514 212, 514 213

Abstract:

In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal.